NCT04695483 (PE-PMA) is a Phase 4 clinical trial of Corifollitropin alfa in Infertility, sponsored by IRCCS San Raffaele.

Who is sponsoring NCT04695483?

NCT04695483 is sponsored by IRCCS San Raffaele.

What drugs are being tested in NCT04695483?

Interventions in NCT04695483: Corifollitropin alfa, Follitropin Beta.

What condition does NCT04695483 study?

NCT04695483 studies Infertility.

Is NCT04695483 still recruiting?

NCT04695483 is currently completed. Last updated 16 May 2024.

Last reviewed 2024-05-16 · How we verify

NCT04695483: PE-PMA

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Reduction of Progesterone Elevation at Trigger in POR After Long Acting COS Compared With Daily COS: a Prospective Randomized Trial

Completed Phase 4 Last updated 16 May 2024

What this trial tests

Phase 4 trial testing Corifollitropin alfa in Infertility in 110 participants. Completed in 6 May 2024.

Timeline

22 February 2022

Primary endpoint
19 January 2024

6 May 2024

Quick facts

Lead sponsor	IRCCS San Raffaele
Phase	Phase 4
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	prevention
Enrollment	110
Start date	22 February 2022
Primary completion	19 January 2024
Estimated completion	6 May 2024
Sites	1 location across Italy

Drugs / interventions tested

Corifollitropin alfa (CORIFOLLITROPIN ALFA) — full drug profile →
Follitropin Beta — full drug profile →

Conditions studied

Infertility — all drugs for Infertility →

Sponsor

IRCCS San Raffaele — full company profile →

Who can join

Adults 25 to 42, female only, with Infertility. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The overarching objective of this research is to generate clinical evidence to argue the benefits of long acting stimulation protocol compared to the daily stimulation protocol in poor ovarian responder bologna' criteria patients after controlled ovarian stimulation. Reduction in the proportion of subjects with progesterone \> 1.1 ng/ml on the day of triggering (day + 13) in the experimental group compared to the control group is expected.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Corifollitropin alfa

Trials testing the same drug.

NCT04482751 — The Relationship Between Serum AMH Dynamics and Early or Normal Ovarian Response to Corifollitropin Alfa · unknown
NCT03019575 — Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (hCG) in Adolesce · Phase 3 · completed
NCT01709331 — A Study of the Efficacy and Safety of Corifollitropin Alfa (MK-8962) in Combination With Human Chorionic Gonadotropin (h · Phase 3 · completed
NCT01146418 — Frozen-thawed Embryo Transfer (FTET) Cycle Follow-up Protocol (P06031) · Phase 3 · completed
NCT00702234 — Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial P05714 (Care Program)(P05715) · completed

Other recruiting trials for Infertility

Currently open trials in the same condition.

NCT07074015 — IntelliWell: An AI-Assisted Imaging Platform for Detection and Location of Ultra-Rare Testicular Sperm in Surgical Speci · NA · recruiting
NCT07358468 — Impact Of FET Preparation Protocol On Endometrial Peristalsis: A Prospective Cohort Study · recruiting
NCT07340827 — A Study to Compare the Efficacy and Safety of Follitropin Alfa/Lutropin Alfa Versus hMG in Japanese Participants With LH · Phase 3 · recruiting
NCT07369362 — To Investigate if the Harvester® Improves Sperm Motility and Blastocyst Utilization (the Percent of Fertilized Eggs That · NA · active not recruiting
NCT07153367 — Using a Fixed Dosage of Follitropin Delta for Ovarian Stimulation for Intrauterine Insemination: Rekovelle for Intrauter · Phase 2 · recruiting

Other IRCCS San Raffaele trials

Trials by the same sponsor.

NCT07454759 — Acute Sarcopenia in Hospitalized Older Adults · not yet recruiting
NCT07456462 — Making Antibody Treatments More Effective in Early Alzheimer's Disease Using 3Tesla Magnetica Resonance · NA · not yet recruiting
NCT07066878 — This Protocol Focuses on the Factors That Influence Survival, the Development of Complications and the Quality of Life B · not yet recruiting
NCT07526298 — Anticipating Irreversible Disability in Neuromyelitis Optica Spectrum Disorder: a Study to Assess Disease Activity in Ap · not yet recruiting
NCT07426471 — Delafloxacin Plasma and Tissue Concentration in Patients With Skin, Soft Tissue, and Bone and Joint Infections. · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04695483 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by IRCCS San Raffaele
Last refreshed: 16 May 2024

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04695483.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing